Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. (HOTH): 12 pipeline candidates · ~4 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.2 months
D/E 0.34 · 0% dilution
Lead: Phase 2
12 candidates
N/A
N/A
A transparent, data-derived signal for Hoth Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$26.0M
Cash
$4.0M
Quarterly Burn
$3.1M
Runway
4.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| biolexa | Phase 1 |
| ht-001 | Phase 2 |
| ht-001 0.5% | Phase 2 |
| ht-001 1% | Phase 2 |
| ht-001 2% | Phase 2 |
| ht-003 | Preclinical |
| ht-004 | Preclinical |
| ht-005 | Preclinical |
| ht-alz | Preclinical |
| ht-kit | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$605K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 259,382 | $218K |
| geode capital management, llc | 214,244 | $180K |
| vanguard fiduciary trust co | 84,318 | $71K |
| state street corp | 63,939 | $54K |
| northern trust corp | 42,054 | $35K |
| xtx topco ltd | 18,129 | $15K |
| two sigma securities, llc | 14,896 | $13K |
| morgan stanley | 10,006 | $8K |
| tower research capital llc (trc) | 7,355 | $6K |
| osaic holdings, inc. | 2,701 | $2K |
Showing top 10 of 16 institutional holders of Hoth Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Hoth Therapeutics, Inc.'s pipeline?
Hoth Therapeutics, Inc. (HOTH) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Hoth Therapeutics, Inc.'s lead drug candidate?
Hoth Therapeutics, Inc.'s most advanced tracked candidate is biolexa (Phase 1) for atopic dermatitis (eczema).
What is Hoth Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Hoth Therapeutics, Inc. has approximately 4.2 months of cash runway.
What is Hoth Therapeutics, Inc.'s market capitalization?
Hoth Therapeutics, Inc.'s market capitalization is approximately $26.0M.
Who is the CEO of Hoth Therapeutics, Inc.?
Mr. Robb Knie is the chief executive officer of Hoth Therapeutics, Inc. (HOTH).
Get the full picture on Hoth Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.